GlassScriptPhysician profile
Gilbert O Plasencia
NPI 1043245822
$3,604.51
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $840 · 2020: $428 · 2021: $378 · 2022: $962 · 2023: $703 · 2024: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $996.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $547.62 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $543.35 | 2019-2024 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $383.99 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $370.40 | 2021-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.91 | 2019-2024 | Jardiance |
| Biotronik INC. | $194.19 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $154.76 | 2019-2023 | |
| Boston Scientific Corporation | $147.21 | 2021-2023 | Watchman Access System |
| Pfizer INC. | $135.48 | 2019-2024 | |
| Kiniksa Pharmaceuticals, LTD. | $118.47 | 2022-2023 | Arcalyst |
| Amgen INC. | $116.36 | 2019-2023 | Repatha |
| Philips North America LLC | $108.68 | 2022-2024 | (5091) Amb Mon & Diag Und |
| E.R. Squibb & Sons, L.L.C. | $107.43 | 2019-2023 | Camzyos |
| Irhythm Technologies, INC. | $95.31 | 2022-2024 | Zio Monitor, Zio Xt Patch |
| Esperion Therapeutics, INC. | $89.65 | 2020-2023 | Nexletol |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $51.11 | 2020-2024 | Impella |
| Cvrx, INC. | $45.28 | 2023 | Barostim Neo System |
| Abbvie INC. | $27.57 | 2021 | |
| Medtronic, INC. | $20.38 | 2021 | |
| Novo Nordisk INC | $19.91 | 2024 | Ozempic |
| Lexicon Pharmaceuticals, INC. | $19.72 | 2023 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.46 | 2022 | |
| Gilead Sciences, INC. | $14.15 | 2019 | |
| Astellas Pharma US INC | $14.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilbert Plasencia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.